Synapse - Unknown

Unknown

SHERPA: Unknown

People

Harding

Groups

Department of Medicine (1)
Gastrointestinal Oncology Service (1)
Solid Tumor Oncology Division (1)

Search Within

Results (1)

Export to EndNote / Excel

HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)

Meeting Abstract

Harding, J. J.; Macarulla, T.; Pant, S.; Wu, X.; Garfin, P. M.; Okusaka, T.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Unknown – authorized name for:

Unknown